Abstract
Summary
Osteoporosis, the most common metabolic bone disease, leads to increased susceptibility to fractures. In 2020, about 150,000 osteoporotic fractures occurred in Iran. Osteoporosis and related fractures cost the community US$ 393 million.
Introduction
The present study aimed at estimating the economic burden of osteoporosis in Iran in 2020.
Methods
We estimated the annual economic burden of osteoporosis in the above 50 years old population using a prevalence-based approach and from a societal perspective. The incidence of osteoporosis and related fractures were estimated based on meta-analysis reports in Iran and international comparisons. The direct medical and non-medical costs as well as the monetary value of quality-adjusted life-years (QALYs) lost because of fractures were estimated. Cost data were extracted from patient records, medical services prices, and previous literature.
Results
A total of 154,530 osteoporotic fractures were estimated in Iran in 2020. The shares of the hip, vertebral, forearm, and other fractures were 14%, 15%, 17%, and 54%, respectively. There were also 3554 deaths from osteoporotic fractures. The economic burden of osteoporosis in Iran was estimated at US$ 393.24 million (US$ 2165 million purchasing power parity 2020). Direct medical and non-medical cost (47.44%), QALY loss (29.65%), and long-term care for prior hip fracture costs (9.4%) were the main component of the economic burden of osteoporosis.
Conclusion
The economic burdens of osteoporosis are significant in Iran. Interventions to prevent osteoporosis and especially associated fractures, such as screening and prophylaxis, can reduce the cost of the disease and improve patients’ quality of life. Further studies are needed to identify cost-effective and feasible interventions in Iran.
Similar content being viewed by others
References
Tootee A, Larijani B (2019) World osteoporosis day: celebrating two decades of progress in preventing osteoporotic fractures in Iran. J Diabetes Metab Disord 18(2):725–727
Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. The Lancet 377(9773):1276–1287
International osteoporosis foundation (IOF). What is osteoporosis. https://www.osteoporosis.foundation. Accessed 2021
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8(1):1–115
Curtis EM, Moon RJ, Harvey NC, Cooper C (2017) Reprint of: The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Int J Orthop Trauma Nurs 26:7–17
Pennestrì F, Corbetta S, Favero V, Banfi G (2019) Fragility fracture prevention—implementing a fracture liaison service in a high volume orthopedic hospital. Int J Environ Res Public Health 16(24):4902
Salari N, Ghasemi H, Mohammadi L, Rabieenia E, Shohaimi S, Mohammadi M (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16(1):1–20
International osteoporosis foundation (IOF). About osteoporosis. https://www.osteoporosis.foundation/patients/about-osteoporosis. Accessed July 2019
Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z (2013) Prevalence of osteoporosis in Iran: a meta-analysis. J Res Med Sci 18(9):759–766
Wong RM, Law S, Lee K, Chow SK, Cheung W (2019) Secondary prevention of fragility fractures: instrumental role of a fracture liaison service to tackle the risk of imminent fracture. Hong Kong Med J 25(3):235–242
Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. British medical bulletin. 2020
Briot K (2017) Fracture liaison services. Curr Opin Rheumatol 29(4):416–421
Tarride J-É, Adachi J, Brown J, Schemitsch E, Slatkovska L, Burke N. Incremental costs of fragility fractures: a population-based matched-cohort study from Ontario, Canada. Osteoporosis International. 2021:1–9
Marcellusi A, Rotundo MA, Nardone C, Sciattella P, Gazzillo S, Rossini M et al (2020) Osteoporosis: economic burden of disease in Italy. Clin Drug Investig 1–10
Mosadeghrad AM, Mousavi A (2021) The futurology of aging population in Iran: Letter to the Editor. Tehran Univ Med J 68(3):66–71
Tanha K, Fahimfar N, Nematollahi S, Sajjadi-Jazi SM, Gharibzadeh S, Sanjari M et al (2021) Annual incidence of osteoporotic hip fractures in Iran: a systematic review and meta-analysis. BMC Geriatr 21(1):1–8
Kanis J, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669–674
Iranian Statistics Center. Statistics-by-Topic/Population: definitions, concepts and statistical survey. https://www.amar.org.ir/english/Statistics-by-Topic/Population. Accessed 2022
Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. The Lancet 353(9156):878–882
Johnell O, Kanis J, Odén A, Sernbo I, Redlund-Johnell I, Petterson C et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15(3):175–179
Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112
Gauthier A, Kanis JA, Jiang Y, Martin M, Compston JE, Borgström F, et al (2011) Gauthier, A., et al., Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Arch Osteoporos 6(1):179–88
Tosteson A, Jönsson B, Grima D, O’Brien B, Black D, Adachi J (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12(10):849–857
Zethraeus N, Borgström F, Ström O, Kanis J, Jönsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18(1):9–23
World Health Organization, Global Health Observatory data repository, Life tables by country. http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en. Accessed 2017
Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–982
Borgström F, Sobocki P, Ström O, Jönsson B (2007) The societal burden of osteoporosis in Sweden. Bone 40(6):1602–1609
Rajabi M, Ostovar A, Sari AA, Sajjadi-Jazi SM, Fahimfar N, Larijani B et al (2021) Direct costs of common osteoporotic fractures (hip, vertebral and forearm) in Iran. BMC Musculoskelet Disord 22(1):1–7
Stevenson M, Davis S, Kanis J (2006) The hospitalisation costs and out-patient costs of fragility fractures. Women’s Health Med 3(4):149–151
Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, et al (2016) A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr 16(1):1–18
Brooks R, Group E (1996) EuroQol: the current state of play. Health Policy 37(1):53–72
Peasgood T, Herrmann K, Kanis J, Brazier J (2009) An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 20(6):853–868
Borgström F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden. Pharmacoeconomics 22(17):1153–1165
Emrani Z, Sari AA, Zeraati H, Olyaeemanesh A, Daroudi R (2020) Health-related quality of life measured using the EQ-5D–5 L: population norms for the capital of Iran. Health Qual Life Outcomes 18(1):1–8
World Bank Open Data. https://data.worldbank.org/country/iran-islamic-rep. Accessed 2022
World Bank Open Data. https://data.worldbank.org/indicator/PA.NUS.ATLS?locations=IR. Accessed 2022
Dimai HP, Redlich K, Peretz M, Borgström F, Siebert U, Mahlich J (2012) Economic burden of osteoporotic fractures in Austria. Heal Econ Rev 2(1):1–10
International osteoporosis foundation (IOF). Burden of osteoporosis. https://www.osteoporosis.foundation/policy-makers/burden-osteoporosis. Accessed 2020
Aziziyeh R, Perlaza JG, Saleem N, Kirazlı Y, Akalın E, McTavish RK et al (2020) The burden of osteoporosis in Turkey: a scorecard and economic model. Arch Osteoporos 15(1):1–9
Ha Y-C, Kim H-Y, Jang S, Lee Y-K, Kim T-Y (2017) Economic burden of osteoporosis in South Korea: claim data of the national health insurance service from 2008 to 2011. Calcif Tissue Int 101(6):623–630
Svedbom A, Ivergård M, Hernlund E, Rizzoli R, Kanis JA (2014) Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos 9(1):1–8
Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K et al (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90(1):53–62
Ahmadi-Abhari S, Moayyeri A, Abolhassani F (2007) Burden of hip fracture in Iran. Calcif Tissue Int 80(3):147–153
Caeiro JR, Bartra A, Mesa-Ramos M, Etxebarría Í, Montejo J, Carpintero P et al (2017) Burden of first osteoporotic hip fracture in Spain: a prospective, 12-month, observational study. Calcif Tissue Int 100(1):29–39
Major G, Ling R, Searles A, Niddrie F, Kelly A, Holliday E et al (2019) The costs of confronting osteoporosis: cost study of an Australian fracture liaison service. JBMR plus 3(1):56–63
Hoang-Kim A, Kanengisser D (2020) Developing registries and effective care models for the management of hip fractures: aligning political, organizational drivers with clinical outcomes. Curr Osteoporos Rep 18(3):180–188
Funding
This study was funded by the Tehran University of Medical Sciences (grant number 9611119004).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
This study was approved by the ethics committee of the Deputy of Research and Technology of the Tehran University of Medical Sciences (IR.TUMS.EMRI.REC.1396.0016). All authors confirm and declare that this study was conducted in compliance with the Declaration of Helsinki. The participants were assured that their information would remain confidential. Informed consent was obtained from all individual participants included in the study.
Conflicts of interest
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(DOCX 101 kb)
Rights and permissions
About this article
Cite this article
Ostovar, A., Mousavi, A., Sajjadi-Jazi, S.M. et al. The economic burden of osteoporosis in Iran in 2020. Osteoporos Int 33, 2337–2346 (2022). https://doi.org/10.1007/s00198-022-06484-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-022-06484-x